


I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on 11/13/08

TOWNSEND and TOWNSEND and CREW LLP

By: 

**PATENT**  
Attorney Docket No.: 082368-007500US  
Client Ref. No.: ONC-A0306P2-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Yusuke NAKAMURA *et al.*

Application No.: 10/573,297

Filed: September 24, 2004

For: METHOD OF DIAGNOSING  
BREAST CANCER

Customer No.: 20350

Confirmation No. 6847

Examiner: Aeder, Sean E.

Art Unit: 1642

**COMMUNICATION UNDER**

**37 C.F.R. §§ 1.821-1.825**

**AND**

**AMENDMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed August 14, 2008, and the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, please consider the following amendments and remarks:

Appl. No. 10/573,297  
Amdt. dated November 11, 2008  
Reply to Office Action of August 14, 2008

PATENT

**Amendments to the Specification** begin on page 3 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 7 of this paper.

**Remarks/ Arguments** begin on page 10 of this paper.

An **Appendix**, including a **Substitute Sequence Listing**, a **Declaration under 37 CFR 1.132**, and **Exhibits A and B**, is included at the end of this paper.